Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Meningioma 7Brain Neoplasms 6Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Laryngeal Neoplasms 2Gliosarcoma 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pharyngeal Neoplasms 1Paranasal Sinus Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Nasopharyngeal Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × Hydroxyurea × Clear all
NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Duke University

Phase 2 Completed
64 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Duke University

Phase 2 Completed
21 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Novartis

Phase 2 Terminated
231 enrolled 12 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡